secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001683168-25-001693
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences FY2024 net loss $4.0M; cash $6.2M; advancing DNase I to IND
-------------------------------------------------------------------------------

- Net loss ~$4.0M for FY2024; R&D expenses fell 5.9% to $3.3M from $3.5M YoY.
- Royalty payments from Takeda sublicense ~$2.5M, relatively flat vs. prior year.
- Cash and cash equivalents at year-end ~$6.2M.
- Continuing DNase I development toward IND/Phase 1 for pancreatic carcinoma.
- Entered Clinical Trial Services Agreement with PeriNess for exploratory studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825001693/0001683168-25-001693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825001693/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-001693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer